Contagion Editorial Team

With the holiday upon us, here are some considerations for dinner prep as well as some recent FDA food recalls.

ACON Laboratories’ Flowflex COVID-19 Antigen Home Test completed the premarket review pathway and is the first test indicated for use in children under 18.

This week read about virus testing, the dosing of one of the COVID-19 vaccines in the pediatric population, HAI grades in hospitals, and live biotherapeutic products in preventing recurrent CDI in older adults with comorbidities.

Valneva’s VLA1553 (Ixchiq) vaccine was shown to met its preliminary endpoint, with 98.9% of participants reaching protective levels of chikungunya virus neutralizing antibodies 1 month after vaccination.

The companies' initial focus will be around Assembly’s established areas of development including hepatitis B and D, as well as herpesviruses.

This antibiotic is the only liquid oral suspension approved in the US.

The formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) is a once-daily treatment for children living with HIV and meant to reduce pill burden.

A congressional subcommittee aims at reducing HIV-related budget items by over half a billion dollars.

A new study finds antimicrobial resistance (AMR) evolves rapidly in patients colonized by diverse P aeruginosa populations due to selection for preexisting resistant strains, demonstrating a clear link between within-host diversity and resistance.

We have developed our new Clinical Corner column and have other ways providers can get involved with Contagion.

The post-hoc gastrointestinal microbiome analyses of recurrent C diff patients from 2 phase 3 studies was shown at the conference.

In phase 3 studies, the company’s investigational therapy, aztreonam-avibactam (ATM-AVI), had favorable results over other treatments used for complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP).

The Mexican Ministry of Health sent the CDC a list of over 200 US patients who may have been exposed to the fungal infection.

Under its final guidance, all prospective blood donors will answer a series of individual, risk-based questions to determine eligibility.

ViiV Healthcare is working with 3 companies to manufacture generic versions of cabotegravir long-acting (LA).

If FDA approved, this 5-in-1 investigational candidate could provide the broadest meningococcal serogroup coverage.

Investigators see a potential new approach to therapeutic development for C diff.

The Lucira COVID-19 & Flu Test is a single-use at-home test kit that provides results from self-collected nasal swab samples in roughly 30 minutes.

In doing so, the country met the new target of the World Health Organization.

The agency would like to begin using individual risk-based questions to reduce the risk of transfusion-transmitted HIV.

The therapies for Clostridioides difficile infection (CDI) saw many developments in recent months and there are more exciting things to come.

They developed clinical guidance and other resources looking to address potential drug interactions with these patient populations who have COVID-19 and may be treated with Paxlovid.

Health programs and efforts to inform the public about the importance of sharing liver education can play a major role in prevention as well as patient care.

A central portal to support clinical practice for patients with or at risk for HIV was launched.

Catch up on all the important news and clinical care topics you may have missed this week.

The revised Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir and ritonavir) allows these providers to offer this COVID-19 therapy.

This past week has been extremely busy in infectious disease with a lot of vaccine news that could impact young children. In addition, GSK reported on its phase 3 study on its RSV vaccine for seniors.

The FDA VRBPAC votes to recommend mRNA vaccines in youngest children; WHO moves to rename monkeypox; Anthony Fauci is diagnosed with COVID-19; and Pfizer stops recruiting for a Paxlovid trial.

GSK’s Priorix MMR vaccine received the federal agency’s approval which was based from data of 6 clinical trials evaluating its safety.